Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression-Reference-Cited by-同舟云学术

Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression

Published:2017-02-21 Issue:4 Volume:18 Page:214-221
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Akram Afia Muhammad¹²,Iqbal Zafar²³,Akhtar Tanveer²,Khalid Ahmed Mukhtar¹,Sabar Muhammad Farooq⁴,Qazi Mahmood Hussain¹,Aziz Zeba⁵,Sajid Nadia⁶,Aleem Aamer⁷,Rasool Mahmood⁸,Asif Muhammad⁹,Aloraibi Saleh¹⁰,Aljamaan Khaled¹¹,Iqbal Mudassar²¹²

Affiliation:

1. Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan

2. Hematology Oncology and Pharmacogenetic Engineering Sciences (HOPES) Group, Health Sciences Research Laboratories, Department of Zoology, University of the Punjab, Lahore, Pakistan

3. Cancer and Medical Genetics, CAMS-A, King Saud Bin Abdulaziz University for Health Sciences & King Abdullah International Medical Research Centre (KAIMRC), King Abdulaziz Medical City, National Guard Health Affairs, Al Ahsa, Saudi Arabia

4. Centre for Applied Molecular Biology (CAMB), University of the Punjab, Lahore, Pakistan

5. Department of Oncology, Hameed Latif Hospital, Lahore, Pakistan

6. Department of Hematology and Oncology, Institute of Nuclear Medicine and Oncology, Lahore, Pakistan

7. College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

8. Centre of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia

9. Department of Biotechnology, Office of Research Innovation and Commercialization, Balochistan University of Information Technology, Engineering and Management Sciences, Quetta, Pakistan

10. College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard- Health Affairs, Riyadh, Saudi Arabia

11. Division of Pediatric Hematology/Oncology, Department of Oncology/King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia

12. Asian Medical Institute, Kant City, & National Surgical Centre, Bishkek, Kyrgyzstan

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2017.1294289

Reference43 articles.

1. Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea

2. The role of dasatinib in the management of chronic myeloid leukemia

3. Resistant mutations in CML and Ph+ALL – role of ponatinib

4. BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study;BMC Research Notes;2024-04-20

2. Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis;Scientia Pharmaceutica;2023-12-25

3. The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure;Leukemia Research;2023-09

4. A Retrospective Analysis of BCR-ABL1 Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory;South Asian Journal of Cancer;2022-12-31

5. The Oncobiome in Gastroenteric and Genitourinary Cancers;International Journal of Molecular Sciences;2022-08-26